title: Anticardiolipin antibodies and vascular access thrombosis in Taiwanese haemodialysis patients with chronic hepatitis C: a retrospective study.
abstract: Hepatitis C virus causes various extrahepatic immunologic abnormalities. Vascular access thrombosis (VAT) is a major cause of morbidity in chronic haemodialysis (HD) patients. Immunoglobulin-G anticardiolipin antibody (IgG-ACA) is strongly associated with venous and arterial thrombosis in patients with normal renal function. Previous investigations have reported the association of raised IgG-ACA titre recurrent with VAT in HD patient, and also few equivalent studies were reported the same in Taiwan. This study attempted to determine whether raised IgG-ACA titres are associated with increased risk of recurrent VAT in HD patients with chronic hepatitis C. This study enrolled 98 chronic hepatitis C patients undergoing HD. IgG-ACA titre and hepatitis C marker were measured for all subjects. Raised IgG-ACA titres were present in 29.6% (29/98) of patients. In both groups (raised and normal IgG-ACA), the type of shunt did not differ (p = 0.416). There was strong association between raised IgG-ACA titre and recurrent VAT (p = 0.0004). In predicting for more or one episodes of VAT using multiple logistic regression, synthetic graft (p < 0.0001), raised IgG-ACA titre (p = 0.039), presence of hepatitis B (p = 0.004) and haemodialysis duration (p = 0.039) were significant factors. The prevalence of raised IgG-ACA titres was 39.6% among chronic hepatitis C with HD patients. There was strong association between raised IgG-ACA titre and recurrent VAT, and this finding may be the consequence of pathogenetic role of raised IgG-ACA titres on the development of VAT status in HD patients with chronic hepatitis C.
authors.affiliation: Division of Nephrology, Chang Gung Memorial Hospital, Kaohsiung Medical Center, Kaohsiung, Taiwan.
authors.forename: C-H
authors.initials: CH
authors.lastname: Lee
authors.forename: I-K
authors.initials: IK
authors.lastname: Wang
authors.forename: T-C
authors.initials: TC
authors.lastname: Chen
authors.forename: H-W
authors.initials: HW
authors.lastname: Chang
authors.forename: C-C
authors.initials: CC
authors.lastname: Yang
authors.forename: Y-S
authors.initials: YS
authors.lastname: Chien
authors.forename: C-S
authors.initials: CS
authors.lastname: Wu
authors.forename: T T-Y
authors.initials: TT
authors.lastname: Chiou
authors.forename: M-S
authors.initials: MS
authors.lastname: Wu
authors.forename: P-H
authors.initials: PH
authors.lastname: Wang
authors.forename: F-R
authors.initials: FR
authors.lastname: Chuang
mesh_terms: D017153:Antibodies, Anticardiolipin / Q000378:metabolism*; D002408:Catheters, Indwelling; D003430:Cross-Sectional Studies; D005260:Female; D006083:Graft Occlusion, Vascular / Q000276:immunology*; D019698:Hepatitis C, Chronic / Q000276:immunology*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000276:immunology* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D006435:Renal Dialysis; D012189:Retrospective Studies; D013927:Thrombosis / Q000276:immunology
chemical_list: D017153:Antibodies, Anticardiolipin